KRRO - Korro Bio Inc. Market Capitalization-to-Revenue Ratio
Korro Bio, Inc. (KRRO) leverages the OPERA platform for precise RNA editing to create a unique therapeutic circuit. The price-to-sales multiple on the GURU.Markets chart reflects market expectations, where 152.80 determines the latest valuation metric. Flexibility is ensured through outsourced manufacturing, while stability is maintained by successfully raising capital to fund preclinical development stages.
Korro Bio, Inc. (KRRO) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Korro Bio, Inc.|KRRO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient korrobio.com|KRRO - Company Debts|Debts to Book Capitalization Korro Bio, Inc|KRRO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Korro Bio|Intermediate Coverage Ratio korrobio.com
- net income and valuation ratios data:
KRRO - Company Net Income|Expected Net Profit Korro Bio, Inc.|KRRO - P/E Multiple|Price to Future Earnings Ratio korrobio.com|KRRO - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Korro Bio, Inc|KRRO - Operating profit EBITDA|Net earnings per share (EPS TTM) Korro Bio|KRRO - Earnings per share for the last twelve months|Quarterly EPS earnings growth korrobio.com|KRRO - Earnings per share growth in current year|Expected net earnings per share growth next year Korro Bio, Inc.
- total revenue and sales volume data:
Fundamental company analysis:KRRO Korro Bio Inc.
Finding a balance between capital preservation and growth potential requires an analysis of the ratio of asset market value to actual cash flows. For Korro Bio, Inc. (KRRO), which focuses on organic RNA editing research without external mergers, the market-to-revenue valuation reflects a premium for future technological breakthroughs, measuring the cost of each unit of current income to determine the fundamental sustainability of the business.
Competitors of Korro Bio, Inc.
TEM - Price to Sales|Qiagen - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|Repligen Corp. - P/S Multiple|Price-to-Revenue Coefficient Avidity Corp RNA|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx) - P/S Multiple|Market Cap to Revenue Beam Therapeutics Inc (BEAM)|Market Cap to Revenue SRPT (Sarepta Therapeutics Inc)|Price-to-Revenue Coefficient Twist Bioscience Corp|Price-to-Revenue Ratio 10x Genomics, Inc. TXG|P/S Multiple intelliatx.com NTLA|STOK - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio BLFS (BioLife Solutions Inc)|Wave Life Sciences Corp (WVE) - Price-to-Revenue Ratio|Maze Therapeutics Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Sionna Therapeutics Inc|Price to Sales primemedicine.com PRME|P/S Multiple TSHA|uniQure NV - Market Cap to Revenue Ratio|Price-to-Revenue Ratio MeiraGTx PLC MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc. - P/S Multiple|OCGN - P/S Multiple|PacBio (PACB) - Price-to-Revenue Ratio|Benitec Biopharma Inc (BNTC) - P/S Multiple|Price-to-Revenue Ratio Design Pharma|Price to Sales Rocket Corp RCKT|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|LXEO (lexeotx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Editas Medicine EDIT|Market Capitalization-to-Revenue Ratio SLN|PRQR - Price-to-Revenue Ratio|Price to Sales Codexis, Inc.|SGMO (Sangamo Therapeutics) - Market Cap to Revenue|Nautilus Bio - Market Capitalization-to-Revenue Ratio|MGX (Metagenomi) - P/S Multiple|Price-to-Revenue Ratio DTIL|P/S Multiple GBIO|Price-to-Revenue Coefficient Boundless Bio Inc|Price-to-Revenue Ratio Exicure XCUR|Imunon Inc (IMNN) - Price to Sales|PHIO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MBIO (Mustang Bio, Inc.)|RNAZ: P/S Multiple|BNGO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Applied DNA Sciences|Market Cap to Revenue Ratio BLUE (bluebirdbio.com)|P/S Multiple IPA|Market Cap to Revenue Omega Therapeutics Inc OMGA|Singular Genomics Systems Inc - Market Cap to Revenue|Price-to-Revenue Coefficient Regulus (RGLS)|SYRS - Price-to-Revenue Ratio|TBIO - P/S Multiple|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology Inc. - Market Capitalization-to-Revenue Ratio
